Rituximab (RTX), a monoclonal antibody targeting the CD20+ B lymphocytes, deserves major attention as therapeutic option in the treatment of demyelinating disorders of the central nervous system (DDCNS). We reported our clinical experience with the use of RTX in terms of efficacy and safety in persons suffering from DDCNS.
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience
D'Amico, EmanueleConceptualization
;Zanghì, AuroraMethodology
;Chisari, Clara Grazia;Fermo, Salvatore Lo;ARENA, SEBASTIANO;Patti, Francesco;Zappia, Mario
2019-01-01
Abstract
Rituximab (RTX), a monoclonal antibody targeting the CD20+ B lymphocytes, deserves major attention as therapeutic option in the treatment of demyelinating disorders of the central nervous system (DDCNS). We reported our clinical experience with the use of RTX in terms of efficacy and safety in persons suffering from DDCNS.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mult. Scler. Rel. Disord. 2019.pdf
solo gestori archivio
Tipologia:
Versione Editoriale (PDF)
Dimensione
1.95 MB
Formato
Adobe PDF
|
1.95 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
